Video Programs

Red blood cell transfusions enhance quality of life for MDS patients but require careful management due to potential risks and long-term effects.

Red blood cell transfusions enhance quality of life for MDS patients but require careful management due to potential risks and long-term effects.

Red blood cell transfusions enhance quality of life for MDS patients but require careful management due to potential risks and long-term effects.

Red blood cell transfusions enhance quality of life for MDS patients but require careful management to avoid complications like iron overload.

Understanding MDS risk classification enhances patient care, focusing on tailored therapies and improving quality of life through effective treatment strategies.

Panelists discuss how emerging targeted agents are poised to reshape the therapeutic landscape for EGFR-mutant NSCLC in the coming years.

Panelists discuss how proactive sequencing strategies optimize long-term outcomes in EGFR-mutant non–small-cell lung cancer (NSCLC) by anticipating resistance patterns.

Panelists discuss how patient-centered counseling and shared decision-making shape personalized treatment journeys in EGFR-mutant non–small-cell lung cancer (NSCLC).

Panelists discuss how adherence to guidelines and vigilant imaging support optimal management of CNS disease in EGFR-mutant non–small-cell lung cancer.

Comprehensive biomarker testing at the time of early NSCLC diagnosis is critical because it ensures that clinicians identify actionable molecular alterations before definitive treatment plans are set.

Panelists discuss how trial data and practical considerations inform the nuanced choice between amivantamab–lazertinib and osimertinib in managing EGFR-mutant non–small-cell lung cancer (NSCLC) with CNS disease.

Panelists discuss how personalized molecular insights drive first-line therapy choices in EGFR-mutant NSCLC with complex metastatic profiles.

Comprehensive biomarker testing in early-stage NSCLC requires coordination across multiple specialties, including thoracic surgery, medical oncology, pathology, pulmonology, and radiology.

Panelists reflect on clinical experience with immunotherapy combinations, the role of biomarkers, and the future of personalized melanoma treatment.

Panelists discuss real-world data comparing outcomes of different immunotherapy combinations for advanced melanoma.

Panelists analyze results from an indirect treatment comparison evaluating different combination immunotherapies in advanced melanoma.

Panelists discuss how addressing current knowledge gaps and improving real-world integration of emerging therapies will advance care for patients with EGFR-mutant non–small cell lung cancer (NSCLC).

Panelists discuss long-term efficacy and safety outcomes from pivotal studies evaluating dual immune checkpoint inhibition in advanced melanoma.

Panelists discuss how dose optimization and personalized adjustment strategies sustain efficacy and enhance long-term outcomes in EGFR-mutant NSCLC.

Panelists discuss how proactive adverse event prevention and patient support improve tolerability and continuity of targeted treatment in EGFR-mutant non–small cell lung cancer (NSCLC).

Panelists discuss current frontline therapeutic strategies for advanced melanoma, highlighting the rationale and evolution of combination immunotherapy approaches.

Panelists discuss how molecular testing and biomarker profiling guide individualized first-line treatment planning for EGFR-mutant non–small cell lung cancer (NSCLC) with central nervous system (CNS) involvement.

An expert discusses how maintenance lurbinectedin benefits patients across subgroups, including those with liver metastases, and may be considered for patients with brain metastases after radiation therapy, while emphasizing the importance of patient counseling about continued chemotherapy expectations.

An expert discusses how maintenance lurbinectedin plus atezolizumab should be followed by standard second-line tarlatamab therapy at progression, as the maintenance approach doesn't change subsequent treatment sequencing.

An expert discusses how moving lurbinectedin to earlier in treatment is justified because 40% to 50% of patients with small cell lung cancer (SCLC) never receive second-line therapy due to rapid disease progression, making proactive treatment essential.

An expert discusses how lurbinectedin maintenance therapy causes primarily hematologic toxicities but has a low discontinuation rate (6.2%), making it suitable for most patients with good performance status and adequate blood count recovery.